ClinicalTrials.gov
ClinicalTrials.gov Menu

Topiramate for Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome (CSPN) (TopCSPN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02878798
Recruitment Status : Recruiting
First Posted : August 25, 2016
Last Update Posted : December 13, 2018
Sponsor:
Collaborators:
National Institute of Neurological Disorders and Stroke (NINDS)
NeuroNEXT Network
University of Utah
Information provided by (Responsible Party):
Virginia Commonwealth University

Brief Summary:
The TopCSPN trial is a double blinded randomized placebo controlled study of oral topiramate as a potential disease altering therapy for cryptogenic sensory peripheral neuropathy (CSPN). Patients with CSPN who also have metabolic syndrome (defined by the ATPIII criteria) who do not have an alternative cause for neuropathy will be potentially eligible. The co primary outcome measures are change in the Norfolk Quality of Life - Diabetic Neuropathy (NQOL-DN) Scale and intraepidermal nerve fiber density (IEFND) at the distal thigh. The treatment phase will last 24 months.

Condition or disease Intervention/treatment Phase
Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome Drug: topiramate Other: Placebo Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 125 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Topiramate as a Disease Modifying Therapy for Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome (CSPN)
Actual Study Start Date : February 12, 2018
Estimated Primary Completion Date : March 2019
Estimated Study Completion Date : December 2021


Arm Intervention/treatment
Placebo Comparator: Placebo
An overencapsulated placebo of identical color, shape and packaging to topiramate will be used.
Other: Placebo
overencapsulated placebo of identical color, shape and packaging to topiramate

Experimental: Topiramate
Oral topiramate
Drug: topiramate
Oral topiramate at a target dose of 50mg twice daily.
Other Name: Topamax




Primary Outcome Measures :
  1. Intraepidermal nerve fiber density (IENFD) [ Time Frame: Baseline 9, 18, and 24 months ]
    Difference in IENFD change between treatment groups over 24 months.

  2. Norfolk Quality of Life - Diabetic Neuropathy [ Time Frame: Baseline, 9, 18, and 24 months ]
    Difference in NQOL between treatment groups over 24 months.


Secondary Outcome Measures :
  1. Nerve conduction studies [ Time Frame: Baseline, 9, 18, and 24 months ]
    association of NCS outcomes to NQOL and IENFD changes

  2. Utah Early Neuropathy Scale [ Time Frame: Baseline, 4, 8, 12, 16, 20, 24 months ]
    association of UENS to NQOL and IENFD changes

  3. Timed up and Go [ Time Frame: Baseline, 9, 18 and 24 months ]
    association of TUG change to NQOL and IENFD changes

  4. 6 Minute Walk Test [ Time Frame: Baseline, 9, 18, and 24 months ]
    association of 6MW change to NQOL and IENFD changes

  5. Neuropathy Total Symptom Score - 6 [ Time Frame: Baseline, 4, 8, 12, 16, 20, 24 months ]
  6. Brief pain inventory [ Time Frame: Baseline, 4, 8, 12, 16, 20, 24 months ]
    association of BPI change to NQOL and IENFD changes



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  1. Age 18-80
  2. Diagnosis of confirmed cryptogenic symptomatic distal symmetric peripheral polyneuropathy based on the Toronto consensus criteria for probable neuropathy (the presence of unequivocal signs and symptoms of neuropathy)
  3. Evidence of symptomatic neuropathy based on a screening visit NQOL-DN score of >9
  4. Metabolic syndrome based on modified ATPIII criteria, with a BMI ≥ 25 kg/m2. Specific criteria require 3 of the following 6 to be present at the screening visit.

    • Waist circumference >102 cm for men, >88 cm for women
    • Serum triglycerides of > 150 mg/dl
    • HDL < 40 mg/dl for men, < 50 mg/dl for women
    • Those with either a normal HDL or TRG who are taking a lipid lowering medication for this purpose.
    • Blood pressure 130/85 mm Hg or use of anti-hypertension drug
    • Prediabetes based on American Diabetes Association (ADA) criteria at screening based on any one or more of the following: fasting plasma glucose - 100 mg/dL to 125 mg/dL (5.6 mmol/L to 6.9 mmol/L), 2-hour glucose tolerance test - 140 mg/dL to 199 mg/dL (7.8 mmol/L to 11.0 mmol/L), or hemoglobin A1c between 5.7% and 6.4%.
  5. No current or prior history of therapy with topiramate.
  6. If female of child-bearing potential (i.e., not surgically sterile or post-menopausal defined as age > 51 years without menses for ≥ 2 years), negative serum pregnancy test at screening and negative urine pregnancy test at baseline visit.
  7. Women of child-bearing potential or men with sexual partners of childbearing potential be willing to use an acceptable method of birth control for the duration of the study and for 12 weeks following completion of study drug therapy. Acceptable methods of birth control include abstinence, oral contraceptives, the contraceptive patch, intra-uterine device, the contraceptive ring, and or barrier contraception such as condoms with spermicide.

Exclusion Criteria

  1. CSS-PI clinical determination of an alternative cause for peripheral neuropathy (including but not limited to rheumatological disorders, Hepatitis B or C, Breast Cancer treated with neurotoxic chemotherapy within the past 15 years). All potential subjects will have screening neuropathy labs including assessment for diabetes (Hemoglobin A1c, oral glucose tolerance test), vitamin B12 level, and immunofixation.
  2. Diagnosis of diabetes by history, or screening laboratory results including: HgA1c ≥ 6.5%, fasting plasma glucose ≥ 126 mg/dL (7.0 mmol/L), or 2-hour oral glucose tolerance ≥ 200 mg/dL (11.1 mmol/L). Borderline screening labs can be repeated within two weeks with PPI approval.
  3. History of recurrent nephrolithiasis, a single episode of nephrolithiasis within one year prior to screening, or use of ongoing preventative treatment.
  4. Family history of a hereditary neuropathy in a first-degree relative.
  5. Severe neuropathy: Utah Early Neuropathy Score > 24 at screening
  6. Active foot ulceration or a history of a nontraumatic foot amputation.
  7. ECG with QTc more than 450 ms in men, or 470 ms in women.
  8. Current or planned therapeutic anticoagulation including coumadin or oral factor X or thrombin inhibitor therapy (anti-platelet agents are permissible).
  9. Chronic corticosteroid use excluding topical or inhaled treatment.
  10. Use of a carbonic anhydrase inhibitor (such as acetazolamide) due to risk of nephrolithiasis.
  11. Planned bariatric surgery
  12. Use of other weight loss medications.
  13. Use of scheduled opiates, or as needed opiate medications more than three times weekly.
  14. Use of topical capsaicin products within 16 weeks of screening or at any time on study.
  15. Medication change for neuropathy symptoms during the 8 weeks prior to screening; or anticipated change for the duration of study participation.
  16. Current use of an intrathecal pain pump or spinal cord stimulator.
  17. Screening laboratory creatinine ≥ 2.0 mg/dl.
  18. Severe edema, dermatologic or lower extremity condition that would increase risk of skin biopsy.
  19. Major depression, bipolar affective disorder, or other mental health disorders that are sufficiently severe to increase adverse event risk or impact neuropathy assessment in the opinion of the responsible site principal investigator.
  20. Current suicidal ideation within one year prior to the baseline visit as evidenced by answering "yes" to Questions 4 or 5 on the suicidal ideation portion of the Columbia-Suicide Severity Rating Scale (C-SSRS).
  21. Ataxia sufficiently severe to represent an unacceptable fall risk in the opinion of the site principal investigator.
  22. A serious medical condition expected to dramatically shorten life span or prevent participation.
  23. Any clinically significant condition or illness, which, in the opinion of the CSS-PI, would pose a risk to the subject or might confound the study including metabolic acidosis, bone marrow suppression, blood dyscrasias, bleeding disorder, or closed angle glaucoma.
  24. History of alcohol or drug abuse within the past two years, or existing neuropathy related to past drug or alcohol abuse.
  25. History of malignancy within five years prior to study enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
  26. A history of epilepsy.
  27. An inability to understand or cooperate with the procedures of the study
  28. Pregnant, or intending to become pregnant, or breastfeeding.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02878798


Contacts
Contact: Gordon Smith, MD 804-828-9556 gordon.smith@vcuhealth.org
Contact: Brittney A Holmberg 804-628-6439 brittney.holmberg@vcuhealth.org

Locations
United States, Alabama
University of Alabama Birmingham Recruiting
Birmingham, Alabama, United States, 35233
Contact: Melanie Benge    205-975-0445    melaniebenge@uabmc.edu   
Principal Investigator: Eroboghene Ubogu, MD         
United States, Colorado
University of Colorado Denver Recruiting
Aurora, Colorado, United States, 80045
Contact: Brianna Blume    303-724-6386    brianna.blume@ucdenver.edu   
Principal Investigator: Dianna Quan, MD         
United States, Florida
University of Miami Recruiting
Miami, Florida, United States, 33136
Contact: Wendy Levy    305-243-6725    wel20@med.miami.edu   
Principal Investigator: Mario Saporta, MD, PhD         
United States, Illinois
Northwestern University Recruiting
Chicago, Illinois, United States, 60611
Contact: Tina Ward    312-503-2128    tina.ward@northwestern.edu   
Principal Investigator: Daniela Menichella, MD, PhD         
United States, Kansas
University of Kansas Medical Center Recruiting
Kansas City, Kansas, United States, 66160
Contact: Chad Parks    913-945-9938    cparks@kumc.edu   
Principal Investigator: Mamatha Pasnoor, MD         
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Contact: Peter James    617-643-4218    pfjames@partners.org   
Principal Investigator: Reza Seyedsadjadi, MD         
United States, Missouri
Washington University School of Medicine Recruiting
Saint Louis, Missouri, United States, 63110
Contact: Mengesha Teshome    314-747-8420    teshomem@wustl.edu   
Principal Investigator: Glenn Lopate, MD         
United States, New York
Columbia University Medical Center Recruiting
New York, New York, United States, 10032
Contact: Arruem Kim    212-305-6036    ak3905@cumc.columbia.edu   
Principal Investigator: Thomas Brannagan, MD         
University of Rochester Medical Center Recruiting
Rochester, New York, United States, 14642
Contact: Janet Sowden    585-275-1267    janet_sowden@urmc.rochester.edu   
Principal Investigator: David Herrmann, MBBCh, MD         
United States, Ohio
Ohio State University Recruiting
Columbus, Ohio, United States, 43221
Contact: Amy Bartlett    614-366-9050    amy.bartlett@osumc.edu   
Principal Investigator: Amro Stino, MD         
United States, Tennessee
Vanderbilt University Medical Center Recruiting
Nashville, Tennessee, United States, 37232
Contact: Kelly Lowen    615-936-0209    kelly.lowen@vumc.org   
Principal Investigator: Amanda Peltier, MD         
United States, Texas
UT Southwestern Medical Center Not yet recruiting
Dallas, Texas, United States, 75390
Contact: Mariam Andersen    214-648-6329    mariam.andersen@utsouthwestern.edu   
Principal Investigator: Lauren Phillips, MD         
United States, Virginia
Eastern Virginia Medical Center Recruiting
Norfolk, Virginia, United States, 23510
Contact: Carolina Caselllini    757-446-7976    casellcm@evms.edu   
Principal Investigator: Aaron Vinik, MD,PhD         
Virginia Commonwealth University Not yet recruiting
Richmond, Virginia, United States, 23298
Contact: Gordon Smith, MD    804-828-9556    gordon.smith@vcuhealth.org   
Contact: Brittney A Holmberg    804-658-6439    brittney.holmberg@vcuhealth.org   
Principal Investigator: Gordon Smith, MD         
Sponsors and Collaborators
Virginia Commonwealth University
National Institute of Neurological Disorders and Stroke (NINDS)
NeuroNEXT Network
University of Utah
Investigators
Principal Investigator: Gordon Smith, MD Virginia Commonwealth University

Responsible Party: Virginia Commonwealth University
ClinicalTrials.gov Identifier: NCT02878798     History of Changes
Other Study ID Numbers: URNN001 / HM20014083
1U01NS095388 ( U.S. NIH Grant/Contract )
First Posted: August 25, 2016    Key Record Dates
Last Update Posted: December 13, 2018
Last Verified: December 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Syndrome
Metabolic Syndrome X
Peripheral Nervous System Diseases
Disease
Pathologic Processes
Insulin Resistance
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases
Neuromuscular Diseases
Nervous System Diseases
Topiramate
Anticonvulsants
Neuroprotective Agents
Protective Agents
Physiological Effects of Drugs
Anti-Obesity Agents